Loading...
NPI 1093136418 · Hayward, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
National Labs Inc is a clinical medical laboratory provider located in Hayward, California. This profile covers 13 Medicare and 38 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | National Labs Inc |
| Address | 3948 Trust Way |
| City | Hayward |
| State | CA |
| ZIP | 94545 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 2, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $51.4M |
| Medicare | $6M |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17,750 | $200 | $3.5M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 13,100 | $60 | $799K |
| 80299 | Use 80299 to report therapeutic drug quantitation procedures that do not have a specific code. | 33,790 | $20 | $608.2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,220 | $240 | $537.5K |
| 83789 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using mass spectrometry and tandem mass spectrometry. | 20,340 | $20 | $488K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 790 | $150 | $120.1K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 130 | $70 | $9.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 100 | $90 | $9.8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 130 | $30 | $3.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 140 | $20 | $3.3K |
Showing 1–10 of 13
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
13 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0482 | 3 | 30 | 70 | $190 | $555.9K |
| G0483 | 14 | 70 | 360 | $240 | $427.9K |
| 83789 | 1 | 10 | 630 | $20 | $165K |
| G0481 | 10 | 50 | 250 | $150 | $131.2K |
| G0480 | 18 | 50 | 70 | $110 | $119.4K |
| G2023 | 69 | 90 | 1,030 | $20 | $110.9K |
| U0005 | 112 | 150 | 780 | $20 | $75.1K |
| U0004 | 28 | 40 | 410 | $70 | $73.6K |
| 80307 | 5 | 150 | 220 | $60 | $69.2K |
| 80299 | 1 | 10 | 260 | $20 | $62.8K |
Showing 1–10 of 13
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
38 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 155,380 | $90 | $14.1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 294,490 | $30 | $8.5M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 50,110 | $140 | $7.1M |
| 83789 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using mass spectrometry and tandem mass spectrometry. | 260,170 | $20 | $4.4M |
| 82542 | The lab analyst performs the technical lab test to evaluate the specimen for the presence or amount of a nondrug analyte by using column chromatography and possibly mass spectrometry. | 108,170 | $40 | $4.3M |
| 80299 | Use 80299 to report therapeutic drug quantitation procedures that do not have a specific code. | 143,030 | $20 | $2.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 30,160 | $80 | $2.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 50,520 | $40 | $2M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 25,250 | $70 | $1.7M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 44,420 | $30 | $1.4M |
Showing 1–10 of 38
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
38 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 60 | 370 | $80 | $4.1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 100 | 520 | $120 | $2.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 70 | 650 | $70 | $1.6M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 54 | 750 | 950 | $50 | $890K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 15 | 150 | 580 | $60 | $608.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 6 | 660 | 1,490 | $30 | $417.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6 | 340 | 970 | $40 | $343.6K |
| 80356 | The lab analyst measures the amount of or detects the presence of heroin metabolite in the patient specimen. | 3 | 20 | 490 | $1 | $275.3K |
| 80353 | The lab analyst measures the amount of or detects the presence of cocaine in the patient specimen. | 4 | 20 | 210 | $1 | $212K |
| 80358 | The lab analyst measures the amount of or detects the presence of methadone in the patient specimen. | 4 | 20 | 330 | $1 | $202.4K |
Showing 1–10 of 38
Other providers in the same ZIP code as National Labs Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Falck Northern California Corp. | CA | Ambulance | $11.3M | $65.1M |
| Alameda Health System | CA | Federally Qualified Health Center (FQHC) | $0 | $32.8M |
| Predicine, Inc. | CA | Clinical Medical Laboratory | $601.3K | $12.3M |
| Qaiser Niaz | CA | Hematology & Oncology Physician | $1.9M | $0 |
| Rishi Kapila | CA | Hospitalist Physician | $500.1K | $0 |
| Rock Liu | CA | Surgery Physician | $77.7K | $0 |
| Jeffrey Yeoh | CA | Certified Registered Nurse Anesthetist | $61.5K | $0 |
| Hans Han | CA | Physician Assistant | $36.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.